Hepatitis C Testing and Linkage to Care

Similar documents
Professor Mark Nelson. Chelsea and Westminster Hospital, London, UK

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US)

Hepatitis C Update: What s New in 2017

Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD

Building Local Capacity for Treatment & Cure

Hepatitis C Care Cascade. At the Dallas County Jail Caroline Abe; Merilyne Aguwa, LVN; Esmaeil Porsa, MD, MPH; Ank E Nijhawan, MD, MPH, MSCS

Hepatitis C in Massachusetts Epidemiology and Public Health Response

Planning for Action at the Local Level

Access to Care and Treatment for HCV Mono-Infection and HIV/HCV Co-Infection

Targeted Outreach & Other Strategies for Increasing HCV Testing

WORKING SESSION: CREATING AN HCV CURE CASCADE

HIV Prevention, Hepatitis Programming, and Drug User Health An Integrated Service Model at SFDPH. Protecting and Promoting Health and Equity

Overcoming barriers to access to hepatitis C treatment in a rapidly changing landscape

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

National Hepatitis C Elimination Program of Georgia

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Accomplishments and Future Directions

HEPATITIS C: UPDATE AND MANAGEMENT

The Dawn of a New Era: Hepatitis C

Miami-Dade County Getting to Zero HIV/AIDS Task Force Implementation Report

Managing New Treatments for Hepatitis C in Primary Care

Discussion Panel: Integrated Testing and Screening From Primary Care to Public Health

HepCure : An innovative web-based toolkit to support the treatment of hepatitis C at community health centers in New York State

Improving Access & Linkage to Care in Underserved Populations & Baby Boomers

Hepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas

HCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD

2017 UnitedHealthcare Services, Inc.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

PATIENT DETAIL Complete for each patient in the sample identified for review. Last Name: First Name: Middle Initial: Medical Record #

Practical Solutions to Reduce Incidence of Liver Cancer. Nancy Steinfurth, Executive Director Liver Health Connection November 2017

Hepatitis C No Barriers to Cure

Epidemiology and Screening for Hepatitis C Infection

Clinical Criteria for Hepatitis C (HCV) Therapy

Numbers HCV and HIV Epidemiology in the US

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Treatment of Patients with HCV and HIV

SFDPH Responds to Hepatitis C: Strategic Directions for and Beyond

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Hepatitis and HIV Co-Infection: Situation in Ukraine.

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

Integrating Hepatitis C into Drug Treatment Settings

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

As a result of this training, participants will be able to:

Strategies to enhance HCV testing, linkage to care and treatment

Genotype 1 Treatment Naïve No Cirrhosis Options

Integrating Hepatitis Services into HIV Programs: The Local Health Department Perspective

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Worldwide Causes of HCC

Patient Discussion Guide

Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C

Hepatitis C Medications Prior Authorization Criteria

Hepatitis C Cure The Invisible Epidemic

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College

HCV epi overview. Brigg Reilley, NPAIHB, Nat l Program Epidemiologist,

HTA: Models, Costs & Benefits.

HIV & HCV in TN: State of the State

Negative Hepatitis C Reporting and Linkage to Care Outreach

Get Hip to Hep: Partnerships for Prevention

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Harvoni: solution to HCV

HCV Testing Challenges & Systems-based Solutions

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

Integrating the ONE CALL Statewide HIV Call Center. Presented by: Tyffany Evans Coleman

As a result of this training, participants will be able to:

WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?

Summary of the risk management plan (RMP) for Olysio (simeprevir)

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Monitoring the HCV care cascade to inform public health action

All Hands on Deck: Taking on Hepatitis C in Tennessee

Engaging and Recruiting Black MSM (BMSM) in the US

JOHNS HOPKINS HEALTHCARE

See Important Reminder at the end of this policy for important regulatory and legal information.

Hepatitis C Resistance Associated Variants (RAVs)

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C

CHRONIC HEPATITIS B AND C COHORT STUDY (CHECS)

Harvoni (sofosbuvir/ledipasvir

Sofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents

Advocating for Sensible Policies in the Age of HCV Cure

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges

New developments in HCV research and their implications for front-line practice

DOB. More than one race or ethnicity Black non-hispanic American Indian/Alaska Native Hispanic. Native Hawaiian/Other Pacific Islander

See Important Reminder at the end of this policy for important regulatory and legal information.

Current trends in CHC 1st genotype treatment

Section 6: Treatment of Hepatitis C virus (HCV)

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18

Data to Care: Improving Health Across the HIV Care Continuum in Colorado

2017 UnitedHealthcare Services, Inc.

Treatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Archived Medical Policy

All four components must be present, but Part A funds to be used for HIV testing only as necessary to supplement, not supplant, existing funding.

PCORI s Hepatitis C Workshop. Arlington, VA October 17, 2014

Lindsey Sizemore, Viral Hepatitis Program Director

Management of Chronic HCV 2017 and Beyond

Mavyret (glecaprevir/pibrentasvir)

Transcription:

Hepatitis C Testing and Linkage to Care Arlene C. Seña, MD, MPH Medical and Laboratory Director, Durham County Department of Public Health Associate Professor, UNC-Chapel Hill, Division of Infectious Diseases January 21,2016

Overview Changing face of HCV in US Guidelines for HCV testing and treatment CDC HCV testing and linkage to care project HCV program at the Durham County Department of Public Health

Estimated Number of Persons Infected with HCV in the US

5000 Treatment Cascades HIV HBV HCV Estimated Patients (in 000 s) 4000 3000 2000 1000 0 ~1,145* ~964* HIV Infected ~84% HIV Diagnosed Up 6%^ ~73% * CDC estimates at the end of 2010 taken from the HIV Surveillance Supplemental Report vol. 18 no. 5. ** Ipsos Healthcare U.S. HIV Monitor Q2 2014. ^ Growth rate calculated as MAT (moving annual total). ~700** On ARV Treatment ~2,000 HBV Chronically Infected ~15% ~300 ~79 HBV Diagnosed ~26% On Oral Antiviral Treatment CDC 12/4/08 Institute of Medicine presentation. Based on Gilead estimates as of Q1 2013. ~4,000 HCV Infected ~40% ~1,600 ~9% HCV Diagnosed ~140 Treated Chak et al 2008, Armstrong et al 2005, Volk et al 2011, Culver et al 2000 Decision resources: CDA AASLD 2012, NHANES 2012, Ipsos Monitor Q1 2014 and Gilead estimates. Data is applicable to the 12 month period beginning January 2014 through December 2014.

HCV Treatment Cascade Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III (2014) The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE 9(7): e101554. doi:10.1371/journal.pone.0101554

HCV Testing Algorithm

HCV Therapy 8-12 week regimen Can be a single pill (with or without ribavirin) Well tolerated but costly 80-90% cure rates Treatment Start Finish Test for Cure 0 12 24

Evolving HCV Treatment Prior to 2011: Pegylated interferon; ribavirin May 2011: Protease inhibitors boceprevir; telaprevir November 2013: Simepravir December 2013: Polymerase inhibitor Sofosbuvir October 2014: Ledipasvir/sofosbuvir November 2014: Simeprevir/sofosbuvir December 2014: Ombitasvir/partaprevir/ritonavir/dasabuvir July 2015: Ombitasvir/paritaprevir/ritonavir; daclatasvir http://hepc.liverfoundation.org/treatment/the-basics-about-hepatitis-c-treatment/advances-in-medications/

CDC RFA PS12-1209 PPHF12 Project Objectives and Strategies, Durham NC To conduct 2000 HCV tests to identify chronic HCVinfected persons not previously aware of their infection in Durham County Targeted screening - STD clinic, homeless clinic, community sites including residential substance abuse recovery program Universal screening Detection center To link a minimum 75% of persons who test positive for HCV RNA to care, treatment, and preventive services. HCV Bridge Counselor (patient navigator) Collaborations with HCV care providers On-site HCV assessment clinics

HCV Testing Results, Durham County, 2012-2014 Testing Facility Total Tests HCV Antibody Positive HCV Antibody Positive/RNA Positive HCV Antibody Negative County Jail 699 87 (12%) 71 (10%) 612 (88%) STD Clinic 773 110 (14%) 82 (10%) 662 (86%) Community Testing Sites Homeless Clinic 1418 272 (19%) 210 (15%) 1146 (81%) 113 32 (28%) 27 (24%) 81 (72%) Total 3003 501 (17%) 390 (13%) 2501 (83%)

HCV Bridge Counselor Role Made first contact with HCV-infected clients Assisted with post-test counseling and control measures Provided education to newly diagnosed persons Alcohol prevention Benefits of treatment Collected drug history, medical history, and contact information Served as the middle person to help facilitate the first doctor s visit

HCV Linkage to Care, Durham County, 2012-2014 Persons identified with chronic HCV infection: 382 Received HCV post-test counseling: 315 (82%) Did not receive HCV posttest counseling: 67 (18%) Referred to HCV care: 227 (59%) Reported already in care or had a primary provider: 16 (4%) Not referred to HCV care: 72 (19%)* Attended first appointment: 187 (49%) Appointment pending: 27 (7%) Missed appointment: 13 (3%) Reasons for not being referred for HCV care: incarceration (n=16), relocation (n=16), refusal of linkage services (n=6), loss to follow-up/could not be located (n=25), or other (n=9).

Lessons Learned HCV testing and linkage to care can be facilitated at the local public health level and integrated with HIV/STI programs. HCV bridge counseling is important to assist patients with barriers to care, including transportation, insurance status, stigma and other concerns about diagnosis. Getting HCV-infected patients to treatment remains problematic due to limited access (e.g. small number of prescribing providers, treatment costs).

FOCUS PROGRAM HIV and Hepatitis C Testing and Linkage to Care in Durham, North Carolina Gilead Sciences, Inc.

The FOCUS Model HIV Routine HIV Screening in Two Health- Care Settings New York City and New Orleans, 2011 2013 HCV Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers Philadelphia, Pennsylvania, 2012 2014

Integrated Testing

Innovative Strategies Maximizing opportunities to provide routine HIV/HCV testing within a human services facility; Offering HIV/HCV screening to clients seeking social services; Co-location of services (primary care clinic within health department) under one roof to assist linkage to care; Creation of an HIV/HCV testing and coordination resource center for the community within the health department.

Questions